Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Neoplasms of the CNS

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 61 articles: HTML format

Single Articles

August 2026
1. STEINDL A, Starzer AM, Tomasich E, Kleinberger M, et al
   Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy.
   Eur J Cancer. 2026;246:116988.
   PubMed     Abstract available
   
   
   
2. DRIJVER AJ, Butterbrod E, Hertler C, Frances SM, et al
   Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).
   Eur J Cancer. 2026;246:116985.
   PubMed     Abstract available
   
   
   June 2026
3. OSTROWSKA B, Domanska-Czyz K, Giza A, Taszner M, et al
   The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.
   Eur J Cancer. 2026;241:116789.
   PubMed     Abstract available
   
   
   May 2026
4. MORFOUACE M, Bielle F, Razis E, McCabe MG, et al
   Response to letter re: Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
   Eur J Cancer. 2026;242:116832.
   PubMed    
   
   
   
5. HASHII Y, Fujisaki H, Terashima K, Goto H, et al
   Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.
   Eur J Cancer. 2026;242:116808.
   PubMed     Abstract available
   
   
   
6. GUO H, Zhou J
   Letter Re "Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations".
   Eur J Cancer. 2026;242:116793.
   PubMed    
   
   
   
7. HAJ MOHAMMAD SF, Spiekman IAC, Verkerk K, Verbeek FAJ, et al
   BRAF(V600E)-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.
   Eur J Cancer. 2026;238:116674.
   PubMed     Abstract available
   
   
   April 2026
8. NEGRIER S, Mourey L, Dalban C, Gross-Goupil M, et al
   Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
   Eur J Cancer. 2026;239:116712.
   PubMed     Abstract available
   
   
   February 2026
9. KISHINANI M, Girish M, Sinha S, Donakonda S, et al
   Single-cell systems network and machine learning dissection of ferroptosis in recurrent glioblastoma highlights astrocytic ZFP36 as a therapeutic hub for network medicine repurposing.
   Eur J Cancer. 2026;237:116591.
   PubMed     Abstract available
   
   
   January 2026
10. LE RHUN E, Sain D, van den Bent M, Franceschi E, et al
    Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma.
    Eur J Cancer. 2026;235:116225.
    PubMed     Abstract available
    
    
    December 2025
11. ISLAM MT, Yang F, Komladzei S, Akhter M, et al
    Integrative machine learning reveals hidden and emerging co-regulatory gene networks for multi-phase glioblastoma outcome prediction.
    Eur J Cancer. 2025;234:116197.
    PubMed     Abstract available
    
    
    
12. BORREGO MR, Lopez-Bravo DP, Vila MM, Perez-Garcia JM, et al
    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
    Eur J Cancer. 2025;233:116161.
    PubMed     Abstract available
    
    
    October 2025
13. VAN LINDER BMH, Brandsma D, Verhoeven E, Jongejan L, et al
    Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid.
    Eur J Cancer. 2025;229:115783.
    PubMed     Abstract available
    
    
    
14. POSTMUS D, Cornelissen JJ, Bogaerts J, Roes KC, et al
    Beyond traditional endpoints: A multi-state modelling approach to integrating morbidity and mortality in cancer treatments evaluation.
    Eur J Cancer. 2025;228:115704.
    PubMed     Abstract available
    
    
    September 2025
15. MCCABE M, Rossi S, Cerza F, Massimino M, et al
    Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results.
    Eur J Cancer. 2025;227:115661.
    PubMed     Abstract available
    
    
    July 2025
16. CAILLOT R, Blom A, Lebbe C, Da Meda L, et al
    Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.
    Eur J Cancer. 2025;227:115637.
    PubMed     Abstract available
    
    
    June 2025
17. MANDALA M, Amaral T, Rutkowski P, Sergi MC, et al
    Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
    Eur J Cancer. 2025;225:115567.
    PubMed     Abstract available
    
    
    May 2025
18. BLOEM M, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, et al
    Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.
    Eur J Cancer. 2025;223:115514.
    PubMed     Abstract available
    
    
    
19. MORFOUACE M, Bielle F, Razis E, Estrade F, et al
    Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
    Eur J Cancer. 2025;223:115493.
    PubMed     Abstract available
    
    
    
20. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    PubMed     Abstract available
    
    
    
21. DESAI AV, Bagchi A, Armstrong AE, van Tilburg CM, et al
    Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
    Eur J Cancer. 2025;220:115308.
    PubMed     Abstract available
    
    
    April 2025
22. LEIBETSEDER A, Berghoff AS
    Response to letter commenting on "Association of pregnancy with tumour progression in patients with glioma".
    Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411.
    PubMed    
    
    
    
23. DANG C, Liu P, Yu X
    Letter Re: Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410.
    PubMed    
    
    
    March 2025
24. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    PubMed     Abstract available
    
    
    January 2025
25. LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al
    Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025;218:115259.
    PubMed     Abstract available
    
    
    
26. PEDERSEN S, Johansen EL, Hojholt KL, Pedersen MW, et al
    Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
    Eur J Cancer. 2025;217:115253.
    PubMed     Abstract available
    
    
    
27. PEARSON AD, Mueller S, Filbin MG, Grill J, et al
    Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Eur J Cancer. 2025;217:115230.
    PubMed     Abstract available
    
    
    December 2024
28. DUERINCK J, Karschnia P, Broekman M, Gempt J, et al
    Addressing the role of surgery in brain tumour trials: A report from the neurosurgery committee of the EORTC brain tumour group.
    Eur J Cancer. 2024;216:115198.
    PubMed     Abstract available
    
    
    
29. DI CARLO D, Annereau M, Vignes M, Denis L, et al
    Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.
    Eur J Cancer. 2024;216:115165.
    PubMed     Abstract available
    
    
    
30. DE GROOT FA, Dekker TJA, Doorduijn JK, Bohringer S, et al
    Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
    Eur J Cancer. 2024;213:115068.
    PubMed     Abstract available
    
    
    November 2024
31. OORT Q, Reijneveld JC, Sikkes SAM, Koekkoek JAF, et al
    Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire.
    Eur J Cancer. 2024;212:114335.
    PubMed     Abstract available
    
    
    September 2024
32. TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al
    Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
    Eur J Cancer. 2024;212:115052.
    PubMed     Abstract available
    
    
    
33. GERRITSEN JKW, Mekary RA, Pisica D, Zwarthoed RH, et al
    Onco-functional outcome after resection for eloquent glioblastoma (OFO): A propensity-score matched analysis of an international, multicentre, cohort study.
    Eur J Cancer. 2024;212:114311.
    PubMed     Abstract available
    
    
    July 2024
34. LE RHUN E, Weller M, Anders C, Larkin J, et al
    "Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools.
    Eur J Cancer. 2024;208:114202.
    PubMed     Abstract available
    
    
    June 2024
35. CHEW SM, Ferraro E, Safonov A, Chen Y, et al
    Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Eur J Cancer. 2024;207:114175.
    PubMed     Abstract available
    
    
    May 2024
36. TRAMA A, Botta L, Stiller C, Visser O, et al
    Survival of European adolescents and young adults diagnosed with cancer in 2010-2014.
    Eur J Cancer. 2024;202:113558.
    PubMed     Abstract available
    
    
    April 2024
37. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
    Eur J Cancer. 2024 Apr 23:114066. doi: 10.1016/j.ejca.2024.114066.
    PubMed    
    
    
    
38. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    PubMed     Abstract available
    
    
    March 2024
39. PICCA A, Touat M, Belin L, Gourmelon C, et al
    REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
    Eur J Cancer. 2024;202:114034.
    PubMed     Abstract available
    
    
    
40. THOMAS-JOULIE A, Tran S, El Houari L, Seyve A, et al
    Prognosis of glioblastoma patients improves significantly over time interrogating historical controls.
    Eur J Cancer. 2024;202:114004.
    PubMed     Abstract available
    
    
    
41. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
    Eur J Cancer. 2024 Mar 8:113981. doi: 10.1016/j.ejca.2024.113981.
    PubMed    
    
    
    February 2024
42. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    PubMed     Abstract available
    
    
    
43. KOCHANEK C, Gilde C, Zimmer L, Ugurel S, et al
    Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Eur J Cancer. 2024;198:113508.
    PubMed     Abstract available
    
    
    January 2024
44. MANDALA M, Lorigan P, Sergi MC, Benannoune N, et al
    Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
    Eur J Cancer. 2024;199:113542.
    PubMed     Abstract available
    
    
    
45. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
    Eur J Cancer. 2024;199:113531.
    PubMed     Abstract available
    
    
    
46. LI Z, Song Y, Farrukh Hameed NU, Yuan S, et al
    Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
    Eur J Cancer. 2024;199:113528.
    PubMed     Abstract available
    
    
    
47. HABRINGER S, Demel UM, Fietz AK, Lammer F, et al
    A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Eur J Cancer. 2024;196:113436.
    PubMed     Abstract available
    
    
    
48. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    PubMed     Abstract available
    
    
    December 2023
49. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
    Eur J Cancer. 2023;198:113475.
    PubMed     Abstract available
    
    
    
50. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    PubMed     Abstract available
    
    
    October 2023
51. LIU D, Wang J
    Re: Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023 Oct 27:113385. doi: 10.1016/j.ejca.2023.113385.
    PubMed    
    
    
    September 2023
52. ROSSIDES M, Mogensen H, Kampitsi CE, Talback M, et al
    Parental occupational exposure to metals and risk of cancer in the offspring: A register-based case-control study from Sweden.
    Eur J Cancer. 2023;191:113243.
    PubMed     Abstract available
    
    
    August 2023
53. DOHM AE, Nakashima JY, Kalagotla H, Jiang SX, et al
    Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
    Eur J Cancer. 2023;192:113287.
    PubMed     Abstract available
    
    
    
54. SOUSSAIN C, Malaise D, Choquet S, Ghesquieres H, et al
    Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral L
    Eur J Cancer. 2023;189:112909.
    PubMed    
    
    
    June 2023
55. PADOVAN M, Maccari M, Bosio A, De Toni C, et al
    Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
    Eur J Cancer. 2023;191:112959.
    PubMed     Abstract available
    
    
    
56. REIJNEVELD JC, Machingura A, Coens C, Taphoorn MJB, et al
    Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Trea
    Eur J Cancer. 2023;190:112946.
    PubMed     Abstract available
    
    
    May 2023
57. DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al
    Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
    Eur J Cancer. 2023;187:161-163.
    PubMed    
    
    
    
58. HERTLER C, Felsberg J, Gramatzki D, Le Rhun E, et al
    Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Eur J Cancer. 2023 May 8:S0959-8049(23)00230-7. doi: 10.1016/j.ejca.2023.
    PubMed     Abstract available
    
    
    April 2023
59. ALAFANDI A, van Garderen KA, Klein S, van der Voort SR, et al
    Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
    Eur J Cancer. 2023;188:122-130.
    PubMed     Abstract available
    
    
    
60. MANACORDA S, Carmena MT, Malone C, Linh Le HM, et al
    Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
    Eur J Cancer. 2023;188:98-107.
    PubMed     Abstract available
    
    
    March 2023
61. CARAMANNA I, Reijneveld JC, van de Ven PM, van den Bent M, et al
    Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023;186:38-51.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum